LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Sana Biotechnology Inc

Chiusa

SettoreSettore sanitario

3.1 -3.73

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.1

Massimo

3.26

Metriche Chiave

By Trading Economics

Entrata

-44M

-94M

Margine di Profitto

-321.09

Dipendenti

194

EBITDA

-48M

-95M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+210.56% upside

Dividendi

By Dow Jones

Utili prossimi

7 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

90M

831M

Apertura precedente

6.83

Chiusura precedente

3.1

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Sana Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 set 2025, 17:03 UTC

I principali Market Mover

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 set 2025, 16:49 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 set 2025, 16:11 UTC

I principali Market Mover

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 set 2025, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline as Yen Strengthens -- Market Talk

16 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 set 2025, 23:20 UTC

Discorsi di Mercato

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 set 2025, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 set 2025, 20:51 UTC

Discorsi di Mercato

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 20:25 UTC

Utili

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 set 2025, 20:24 UTC

Utili

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 set 2025, 19:19 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 set 2025, 18:52 UTC

Discorsi di Mercato

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 set 2025, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 set 2025, 18:38 UTC

Discorsi di Mercato

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 set 2025, 18:19 UTC

Discorsi di Mercato

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 set 2025, 18:01 UTC

Discorsi di Mercato

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 set 2025, 17:34 UTC

Discorsi di Mercato

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 set 2025, 16:53 UTC

Utili

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 set 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 16:15 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Commodities Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Energy Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 set 2025, 15:22 UTC

Discorsi di Mercato

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 set 2025, 15:21 UTC

Discorsi di Mercato

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Confronto tra pari

Modifica del prezzo

Sana Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

210.56% in crescita

Previsioni per 12 mesi

Media 10 USD  210.56%

Alto 12 USD

Basso 5 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sana Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.68 / 1.87Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat